- PROFESSOR | Medicine, Gastroenterology
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai St. Luke's and Mount Sinai West
- Feinstein IBD Clinical Center 212-241-8100212-241-8100
- Celiac Disease
- Colon Polypectomy
- Colon Polyps
- Crohn's Disease
- Inflammatory Bowel Disease
- Ulcerative Colitis
MD, Columbia Univ. Col. of Phy. & Surg.
Residency, Internal Medicine
Columbia-Presbyterian Medical Ctr.
Residency, Internal Medicine
Columbia-Presbyterian Medical Center
Mount Sinai Hospital
A Double-Blind Randomized Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This is a Phase 3 double-blind randomized multicenter study of higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active UC. This study will include a 3-Week Screening Period; an 8-Week Double-Blind Indu...
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications
The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab IV), a tumor necrosis factor (TNF) antagonist (adalimumab SC), and an immunomodulator (oral methotrexate) on endoscopic remission at Week 26. Subjects may qual...
Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's Disease. [MLN-0002_401]
Entyvio PASS is a long-term safety observational study to look at the safety and efficacy of vedolizumab compared to other biologic agents in treating Inflammatory Bowel Disease (IBD) such as Crohn's Disease (CD) and Ulcerative Colitis (UC). Vedolizumab was approved by the FDA on...
A Multicenter Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regiments in Subjects with Moderately Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
This is a randomized double-blind multicenter study of two adalimumab induction regimens in subjects with moderately to severely active Crohn's Disease (CD) with evidence of mucosal ulceration confirmed by central reading. No placebo arm is planned since there is well-documented ...
A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease
This is a 40-week open-label extension study designed to evaluate the long-term efficacy, safety, and tolerability of adalimumab. The purpose of this study is to evaluate the long-term efficacy, safety and tolerability of repeated subcutaneous (under the skin injection) admini...
A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis (A3921139)
The purpose of this research study is to assess the safety and tolerability of long-term tofacitinib therapy in patients with Ulcerative Colitis (UC). A3921139 is an open label study, which means that tofacitinib (also known as tofacitinib citrate or CP-690,550) is given to all p...
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis
The purpose of this study is to evaluate the safety of alicaforsen enema, and how well patients tolerate the enema, as well as how it affects their symptoms of pouchitis. Pouchitis is the name given to the inflammation that a patient experiences in their ileal pouch. In the plann...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Marion during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Janssen Biotech, Inc., formerly Centocor Biotech, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.